Results 141 to 150 of about 8,866 (177)

Outbreak of immediate-type hydrolyzed wheat protein allergy due to a facial soap in Japan [PDF]

, 2017
Aihara Michiko, Chinuki Yuko, Fukushima Atsuki, Fukutomi Yuma, Hide Michihiro, Ikezawa Zenro, Itagaki Yasuharu, Kato Zenichiro, Kishikawa Reiko, Matsunaga Kayoko, Morita Eishin, Nakamura Masashi, Noguchi Emiko, Saito Hirohisa, Sugiura Shin-ichi, Tanaka Hiroyuki, Teshima Reiko, Urisu Atsuo, Yagami Akiko, 野口 惠美子   +19 more
core   +2 more sources

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia [PDF]

, 2018
AG Evans, B Mizukawa, FM Vega, G Pillinger, H Wu, HP Kuo, HS Kuehn, J Wei, K Bence, L Zaitseva, M Konopleva, MA Ayoub, MY Murray, R Schrage, S Tavor, SA Rushworth, SP Xu, T Oellerich, TL Gu   +18 more
core   +1 more source

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B‑Cell Signaling

ACS Omega, 2017
Einav Ratzon, Itai Bloch, Meshel Nicola, Elad Cohen, Nili Ruimi, Nesly Dotan, Meytal Landau, Maayan Gal   +7 more
doaj   +1 more source

The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia. [PDF]

Front Oncol
Yang S, Wei R, Shi H, Wang Y, Lai Y, Zhao X, Lu J, Schmitz N.   +7 more
europepmc   +1 more source

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. [PDF]

J Manag Care Spec Pharm
Huntington SF, Manzoor BS, Jawaid D, Puckett JT, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi JA.   +7 more
europepmc   +1 more source

Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. [PDF]

Signal Transduct Target Ther, 2020
Liu J, Liang Q, Wang A, Zou F, Qi Z, Yu K, Liu Q, Chen C, Liu J, Liu Q.   +9 more
europepmc   +1 more source

Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques [PDF]

, 2018
Busygina, Bye, Bye, Byrd, Jamasbi, Levade   +5 more
core   +1 more source

Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. [PDF]

Mult Scler
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.   +13 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

Pseudo-Acute Kidney Injury With Tyrosine Kinase Inhibitors: Utility of the Creatinine-to-Cystatin C Ratio. [PDF]

Kidney Int Rep
Rodrigues N, Shah CV.
europepmc   +1 more source